Outset Medical (OM) Projected to Post Earnings on Wednesday

Outset Medical (NASDAQ:OM) is expected to be posting its quarterly earnings results after the market closes on Wednesday, February 19th. Analysts expect Outset Medical to post earnings of ($0.42) per share and revenue of $28.47 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Outset Medical Stock Performance

OM opened at $0.79 on Wednesday. The firm has a market cap of $42.68 million, a PE ratio of -0.29 and a beta of 2.01. The company has a quick ratio of 5.04, a current ratio of 6.49 and a debt-to-equity ratio of 4.12. The business has a fifty day simple moving average of $1.00 and a 200-day simple moving average of $0.94. Outset Medical has a fifty-two week low of $0.44 and a fifty-two week high of $5.22.

Insider Transactions at Outset Medical

In other news, CEO Leslie Trigg sold 65,236 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $0.80, for a total value of $52,188.80. Following the completion of the sale, the chief executive officer now owns 895,580 shares of the company’s stock, valued at $716,464. This trade represents a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel John L. Brottem sold 32,930 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $0.80, for a total value of $26,344.00. Following the completion of the sale, the general counsel now directly owns 181,188 shares of the company’s stock, valued at approximately $144,950.40. This trade represents a 15.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 282,234 shares of company stock valued at $233,798 in the last three months. 4.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada reissued a “sector perform” rating and set a $3.00 price objective on shares of Outset Medical in a research note on Tuesday, January 7th.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.